Rivera P, Inostroza J, Orio M
Actas Urol Esp. 1996 Oct;20(9):812-7.
It was carried out a study of lymphocytes CD3, CD8 and cytokines in the blood of 13 patients, with superficial bladder cancer, and treated by instillations with BCG vaccine, with a dose of 1 mg. in an annual scheme, being related them before and after treatment. A control group of 10 patients without bladder cancer and without vaccine instillations were compared. The measurings took place in a blind way, previous to BCG treatment, 15 days, 3 days, 3 months, 6 months and 12 months of treatment. It was observed in postBCG treatment, a significative increase in the count of CD3 lymphocytes and the CD4/CD8 cociente (both, P < 0.05). Concerned to cytokines, a significative increase was only demonstrated by interleukin-2 in the post BCG group (P < 0.05). In both (lymphocytes and cytokines) the control groups didn't demonstrate statistics signification. The studies where analysed by means of ANDEVA test, under 2 x 2 cross over design, student t and no parametric tests. In conclusion, bladder instillations of 1 mg. of BCG vaccine as prophylactic treatment of superficial bladder cancer, it's capable of developing lymphocytic answer and stimulate the increase of interleukin-2 in the serum.